Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial.

Reynolds MR, Lin J, Jhaveri M, Mozaffari E, Plich A.

Am J Ther. 2014 Nov-Dec;21(6):500-8. doi: 10.1097/MJT.0b013e31826fc43c.

PMID:
23344106
2.

Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.

Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL.

Clin Cardiol. 2010 May;33(5):270-9. doi: 10.1002/clc.20759.

3.

Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.

Kim MH, Lin J, Jhaveri M, Koren A.

Adv Ther. 2014 Mar;31(3):318-32. doi: 10.1007/s12325-014-0108-x. Epub 2014 Mar 5.

4.

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study.

Torp-Pedersen C, Crijns HJ, Gaudin C, Page RL, Connolly SJ, Hohnloser SH; ATHENA Investigators.

Europace. 2011 Aug;13(8):1118-26. doi: 10.1093/europace/eur102. Epub 2011 May 15.

5.

Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).

Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Pedersen C, Hohnloser SH; ATHENA Investigators.

Am J Cardiol. 2011 Apr 1;107(7):1019-22. doi: 10.1016/j.amjcard.2010.11.028. Epub 2011 Feb 4.

PMID:
21296333
6.

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.

Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH; ATHENA Investigators.

Circulation. 2009 Sep 29;120(13):1174-80. doi: 10.1161/CIRCULATIONAHA.109.875252. Epub 2009 Sep 14.

7.

Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.

Åkerborg Ö, Nilsson J, Bascle S, Lindgren P, Reynolds M.

Clin Ther. 2012 Aug;34(8):1788-802. doi: 10.1016/j.clinthera.2012.06.007. Epub 2012 Jul 6.

PMID:
22770643
8.

Post-ATHENA and beyond.

Naccarelli GV.

J Interv Card Electrophysiol. 2011 Jun;31(1):55-60. doi: 10.1007/s10840-011-9550-8. Epub 2011 Feb 19.

PMID:
21336617
9.

Dronedarone for the treatment of atrial fibrillation and atrial flutter.

Maund E, McKenna C, Sarowar M, Fox D, Stevenson M, Pepper C, Palmer S, Woolacott N.

Health Technol Assess. 2010 Oct;14(Suppl. 2):55-62. doi: 10.3310/hta14suppl2/08. Review.

10.

Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial.

Berg J, Sauriol L, Connolly S, Lindgren P.

Can J Cardiol. 2013 Oct;29(10):1249-55. doi: 10.1016/j.cjca.2013.01.016. Epub 2013 Apr 24.

PMID:
23623647
12.

Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial.

Pisters R, Hohnloser SH, Connolly SJ, Torp-Pedersen C, Naditch-Brûlé L, Page RL, Crijns HJ; ATHENA Investigators.

Europace. 2014 Feb;16(2):174-81. doi: 10.1093/europace/eut293. Epub 2013 Sep 26.

13.

Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.

Wolbrette D, Gonzalez M, Samii S, Banchs J, Penny-Peterson E, Naccarelli G.

Vasc Health Risk Manag. 2010 Aug 9;6:517-23. Review.

14.

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators.

N Engl J Med. 2007 Sep 6;357(10):987-99.

15.

Dronedarone in high-risk permanent atrial fibrillation.

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators.

N Engl J Med. 2011 Dec 15;365(24):2268-76. doi: 10.1056/NEJMoa1109867. Epub 2011 Nov 14. Erratum in: N Engl J Med. 2012 Feb 16;366(7):672.

16.

Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.

Duray GZ, Schmitt J, Hohnloser SH.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):19S-23S. doi: 10.1177/1074248410368530. Epub 2010 May 14.

PMID:
20472812
17.

Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model.

Reynolds MR, Nilsson J, Akerborg O, Jhaveri M, Lindgren P.

Clinicoecon Outcomes Res. 2013;5:19-28. doi: 10.2147/CEOR.S36019. Epub 2013 Jan 8.

18.

A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.

Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):24S-30S. doi: 10.1177/1074248410368276. Review.

PMID:
21098416
19.

Efficacy and safety of dronedarone: a review of randomized trials.

Christiansen CB, Torp-Pedersen C, Køber L.

Expert Opin Drug Saf. 2010 Jan;9(1):189-99. doi: 10.1517/14740330903514105. Review.

PMID:
20001756
20.

Dronedarone: drondarone, SR 33589, SR 33589B.

[No authors listed]

Drugs R D. 2007;8(3):171-5. Review.

PMID:
17472412
Items per page

Supplemental Content

Write to the Help Desk